ITGAM and glioma: Consistent with our results, Jordan and Waxman observed anti-tumor effects in an immunogenic glioma model, using low-dose CY plus a B-class CpG-ODN, and showed an increase in intratumoral CD11b+ F4/80+ myeloid cells, NK cells, DCs and T cells, as well as immunologic memory [47].